Home > Resources > Whitepapers > Effective solutions for global challenges

Industrial Impact

Effective solutions for global challenges

April 24, 2023

Effective solutions for global

Despite challenging global conditions, the Swiss biotech industry was able to raise more than CHF 1.33 billion in 2022, with roughly CHF 0.78 billion collected by public companies and the remaining CHF 0.55 billion collected by private companies.

Spotlight

Eligo Bioscience

Eligo Bioscience is a young biotech that develops smart antibiotics for microbiome precision-editing. Eligo Bioscience is a laureate of the Worldwide Innovation Challenge, Concours National d'Aide à la Création d'Entreprise Innovante 2014 and Tremplin Entreprises 2015. We are currently located at Institut Pasteur in Paris.

OTHER WHITEPAPERS

Taking the Lead on Lab Cybersecurity

whitePaper | October 21, 2022

Just as thieves developed a new interest in explosives following the 1861 invention of the combination lock—and the concurrent rise in the popularity of bank vaults.

Read More

GMP Grade PMSF and Protease Inhibitors

whitePaper | February 23, 2023

Phenylmethylsulfonyl fluoride, better known as PMSF, is a small molecule serine protease inhibitor used to prevent unwanted proteolysis.

Read More

Early engagement and regulatory considerationsfor biotech

whitePaper | May 10, 2022

Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from small molecules, large molecules, and biologics to genomic medicines

Read More

Growing a circular economy with fungalbiotechnology

whitePaper | October 22, 2022

Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct opportunities for tackling the urgent challenges before all humans

Read More

bFGF Supports Human ES Cell Self-Renewal

whitePaper | March 24, 2023

Basic fibroblast growth factor (bFGF) is an important cytokine used to support the growth and self renewal of human embryonic stem cells.

Read More

Are Nitrosamines a Concern for Biologic Manufacturers?

whitePaper | March 30, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk.

Read More

Taking the Lead on Lab Cybersecurity

whitePaper | October 21, 2022

Just as thieves developed a new interest in explosives following the 1861 invention of the combination lock—and the concurrent rise in the popularity of bank vaults.

Read More

GMP Grade PMSF and Protease Inhibitors

whitePaper | February 23, 2023

Phenylmethylsulfonyl fluoride, better known as PMSF, is a small molecule serine protease inhibitor used to prevent unwanted proteolysis.

Read More

Early engagement and regulatory considerationsfor biotech

whitePaper | May 10, 2022

Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from small molecules, large molecules, and biologics to genomic medicines

Read More

Growing a circular economy with fungalbiotechnology

whitePaper | October 22, 2022

Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct opportunities for tackling the urgent challenges before all humans

Read More

bFGF Supports Human ES Cell Self-Renewal

whitePaper | March 24, 2023

Basic fibroblast growth factor (bFGF) is an important
cytokine used to support the growth and self renewal of
human embryonic stem cells.

Read More

Are Nitrosamines a Concern for Biologic Manufacturers?

whitePaper | March 30, 2023

The discovery of nitrosamine genotoxins in several
pharmaceuticals has led to monitoring and re-evaluation of
manufacturing practices for those products considered atrisk.

Read More

More Whitepapers

Spotlight

Eligo Bioscience

Eligo Bioscience is a young biotech that develops smart antibiotics for microbiome precision-editing. Eligo Bioscience is a laureate of the Worldwide Innovation Challenge, Concours National d'Aide à la Création d'Entreprise Innovante 2014 and Tremplin Entreprises 2015. We are currently located at Institut Pasteur in Paris.

Events